U.S. federal trademark · Serial No. 98209503
Pharmaceutical and biological preparations based on base editing, base modification, nucleobase editing, nucleobase modification, nucleic acid editing, gene editing, gene modification, gene modulation, gene reprogramming, gene therapy, genome editing, genome modification, cell therapy, cellular modification, tissue modification, and organ modification for use in human therapeutics for the treatment of Sickle Cell Disease, Beta Thalassemia, Alpha-1 Antitrypsin Deficiency, Glycogen Storage Disease Ia, Cancer, T-Cell Cancer, T-Cell Acute Lymphoblastic Leukemia, CD7 positive Acute Myeloid Leukemia, and Stargardt Disease
Source: USPTO federal trademark records. Informational only, not legal advice. Status and details may lag the live USPTO database.